Minerva Neurosciences (NERV) Tops Q2 EPS by 12c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/14/2026
- Wall Street ends higher as SpaceX's market debut dominates
- SpaceX prices historic IPO at $135/share in largest ever new listing
- 'Ocean of opportunity': Wolfe initiates SpaceX at Buy ahead of historic IPO
- UBS cuts gold price forecasts on delayed Fed easing outlook
- Brent falls to lowest since March on expected peace deal
- NASDAQ adds five companies to NASDAQ-100 index in quarterly rebalance
- Super Micro Computer establishes $1.25 billion stock sale agreement
- Wall Street ends higher as SpaceX's market debut dominates
- 'Ocean of opportunity': Wolfe initiates SpaceX at Buy ahead of historic IPO
- SpaceX Shares Indicated To Open At $155
Minerva Neurosciences Reports Second Quarter 2016 Financial Results and Business Updates
August 4, 2016 7:30 AM EDTPositive clinical data advance development with MIN-101 in schizophrenia and MIN-117 in major depressive disorder
Additional trials also planned with MIN-202 in insomnia disorder and major depressive disorder
WALTHAM, Mass., Aug. 04, 2016 (GLOBE NEWSWIRE) -- Â Minerva Neurosciences, Inc. (NASDAQ: NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous system (CNS) disorders, today reported key business updates and financial results for the quarter ended June 30, 2016.
Positive data announced during the second quarter of 2016 reinforced the differentiated product... More
